Proactive Investors - Run By Investors For Investors

Horizon Discovery can be transformed by Dharmacon acquisition suggests RBC

Horizon has acquired complementary products and a platform with real potential to exploit
picture of cells
Dharmacon has three product ranges targeting academics (60% of revenue) and industry.

Horizon Discovery Group PLC’s (LON:HZD) acquisition of Dharmacon looks inexpensive and has the potential to transform the business believes broker RBC Capital.

The consideration is US$85mln, which is 2.3 times Dharmacon revenues but more importantly Horizon has acquired complementary products and a platform with real potential to exploit.

“We see the strategic rationale, we believe it can be transformational, but will want to see more delivery on specific revenue synergies before putting through any significant revenue or valuation upgrades (particularly as Horizon picked up the business so cheaply in our view).”

Shares surged on the news of the deal, but if management can combine both entities successfully there is greater potential from the whole than the parts.

Dharmacon has seen top line revenue decline but Horizon management are confident on ‘mid to high single digit revenue’ in 2017 and given the potential for sales synergies Dharmacon's top line revenues can rise by 6% annually.

The risk is the promise may take some time to deliver, hence a hold rating though the broker’s price target rises to 245p from 220p.

Shares today were 257p, up 2%.

View full HZD profile View Profile

Horizon Discovery Group PLC Timeline

Related Articles

1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use